Regulus Therapeutics Balance Sheet - Quarterly (NASDAQ:RGLS)

Add to My Stocks
$0.19 $0 (0%) RGLS stock closing price Sep 20, 2018 (Closing)

A thorough fundamental analysis involves using data from Regulus Therapeutics balance sheet, apart from other financial statements, to value the business. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our Regulus Therapeutics stock analysis. Quarterly results announcements include the release of all three financial statements, of which the balance sheet is one. The Regulus Therapeutics balance sheet for 2018 Q2 shows total assets of $49.17M. The company has a asset turnover ratio of 0. Also see: Regulus Therapeutics revenue and Regulus Therapeutics operating cash flow for the same quarter.

View and download Regulus Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Cash13.49M10.05M13.51M20.22M12.53M14.88M14.94M14.78M27.5M20.16M
Marketable Securities19.37M35.07M46.55M51.14M27.54M42.57M61.17M76.87M80.5M85.84M
Receivables------1.65M---
Inventory----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets6.19M6.1M6.28M7.66M9.16M9.74M9.7M10.88M8.08M9.68M
Total Current Assets
39.23M51.42M66.73M79.56M49.94M67.64M87.47M102.83M116.23M115.75M
Property Plant & Equipment--17.96M---19.63M---
Accumulated Depreciation--8.25M---7.8M---
Net Property Plant & Equipment
8.91M9.3M9.7M10.17M10.75M11.27M11.83M12.04M12.32M10.95M
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Intangibles------1.01M1.05M1.06M1.06M
Deposits & Other Assets----------
Total Assets
49.17M62.07M77.8M90.84M61.86M80.17M100.66M116.26M129.92M128.13M
Notes Payable----------
Accounts Payable5.47M4.39M5.74M5.22M4.9M4.5M5.84M5.72M3.5M3.62M
Current Portion Long-Term Debt19.89M19.87M19.85M-------
Current Portion Capital Leases----------
Accrued Expenses3.31M4.48M6.92M6.45M6.15M5.99M7.89M7.35M7.33M6.66M
Income Taxes Payable----------
Other Current Liabilities2.13M2.17M--------
Total Current Liabilities
30.8M30.93M32.6M11.75M11.12M10.57M13.8M13.15M11.09M11.01M
Mortgages----------
Deferred Taxes/Income7.46M7.77M9.99M10.31M10.62M10.83M10.83M2.01M2.02M2.04M
Convertible Debt----------
Long-Term Debt---19.84M19.83M19.81M19.8M19.78M19.78M-
Non-Current Capital Leases----------
Other Long-Term Liabilities-------8.63M8.57M7.85M
Total Liabilities
38.74M39.2M42.59M42.26M41.86M41.44M44.58M43.58M41.48M20.9M
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus384.3M382.93M381.1M379.99M335.61M332.74M329.49M326.07M322.28M319.99M
Retained Earnings-373.89M-360.04M-345.85M-331.41M-315.58M-293.97M-273.35M-253.33M-233.81M-212.72M
Treasury Stock----------
Other Liabilities-0.08M-0.12M-0.13M-0.1M-0.08M-0.09M-0.12M-0.11M-0.08M-0.09M
Shareholders Equity10.43M22.87M35.21M48.58M19.99M38.72M56.07M72.68M88.44M107.22M
Total Liabilities & Shareholders Equity49.17M62.07M77.8M90.84M61.86M80.17M100.66M116.26M129.92M128.13M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Apart from balance sheet items, an investor would do well to keep track of the Regulus Therapeutics stock price by looking at Regulus Therapeutics historical stock prices. One can compare PE with industry average by looking at the Regulus Therapeutics PE ratio chart. The common balance sheet items are:

  • Assets: RGLS total assets, which was at $49.17M for 2018 Q2 is a balance sheet item representing value of what Regulus Therapeutics owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Regulus Therapeutics is $38.74M. Shareholders equity comes under liabilities as it is money the company owes the holders of RGLS stock.

Regulus Therapeutics Balance Sheet - Key Ratios

Current ratio
1.27
Debt to equity ratio
1.91
Asset turnover ratio
0
Receivables turnover
0.21
Price to book ratio
0.71